These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38655111)

  • 1.
    Lee JY; Kim HY; Martorano P; Riad A; Taylor M; Luedtke RR; Mach RH
    Front Neurosci; 2024; 18():1380009. PubMed ID: 38655111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography.
    Landwehrmeyer B; Mengod G; Palacios JM
    Eur J Neurosci; 1993 Feb; 5(2):145-53. PubMed ID: 8261096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Governing Selectivity of Dopamine Receptor Binding Compounds for D2R and D3R Subtypes.
    Hayatshahi HS; Luedtke RR; Taylor M; Chen PJ; Blass BE; Liu J
    J Chem Inf Model; 2021 Jun; 61(6):2829-2843. PubMed ID: 33988991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of bitopic ligands based on fallypride and evaluation of their affinity and selectivity towards dopamine D
    Tian GL; Hsieh CJ; Taylor M; Lee JY; Riad AA; Luedtke RR; Mach RH
    Eur J Med Chem; 2023 Dec; 261():115751. PubMed ID: 37688938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current drug treatments targeting dopamine D3 receptor.
    Leggio GM; Bucolo C; Platania CB; Salomone S; Drago F
    Pharmacol Ther; 2016 Sep; 165():164-77. PubMed ID: 27343365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D3 receptor binding of (18)F-fallypride: Evaluation using in vitro and in vivo PET imaging studies.
    Mukherjee J; Constantinescu CC; Hoang AT; Jerjian T; Majji D; Pan ML
    Synapse; 2015 Dec; 69(12):577-91. PubMed ID: 26422464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging a Low-Affinity Diazaspiro Orthosteric Fragment to Reduce Dopamine D
    Reilly SW; Riad AA; Hsieh CJ; Sahlholm K; Jacome DA; Griffin S; Taylor M; Weng CC; Xu K; Kirschner N; Luedtke RR; Parry C; Malhotra S; Karanicolas J; Mach RH
    J Med Chem; 2019 May; 62(10):5132-5147. PubMed ID: 31021617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative autoradiographic studies of dopamine D3 receptors in rat cerebellum using [125I]S(-)5-OH-PIPAT.
    Vessotskie JM; Kung MP; Chumpradit S; Kung HF
    Brain Res; 1997 Dec; 778(1):89-98. PubMed ID: 9462880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional and source-based patterns of [
    Worhunsky PD; Matuskey D; Gallezot JD; Gaiser EC; Nabulsi N; Angarita GA; Calhoun VD; Malison RT; Potenza MN; Carson RE
    Neuroimage; 2017 Mar; 148():343-351. PubMed ID: 28110088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor.
    Adhikari P; Xie B; Semeano A; Bonifazi A; Battiti FO; Newman AH; Yano H; Shi L
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33924613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and evaluation of bitopic arylpiperazine-phthalimides as selective dopamine D
    Cao Y; Sun N; Zhang J; Liu Z; Tang YZ; Wu Z; Kim KM; Cheon SH
    Medchemcomm; 2018 Sep; 9(9):1457-1465. PubMed ID: 30288220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic doses of buspirone block D3 receptors in the living primate brain.
    Kim SW; Fowler JS; Skolnick P; Muench L; Kang Y; Shea C; Logan J; Kim D; Carter P; King P; Alexoff D; Volkow ND
    Int J Neuropsychopharmacol; 2014 Aug; 17(8):1257-67. PubMed ID: 24679922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.
    Rangel-Barajas C; Malik M; Taylor M; Neve KA; Mach RH; Luedtke RR
    J Neurochem; 2014 Nov; 131(4):418-31. PubMed ID: 25041389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single glycine in extracellular loop 1 is the critical determinant for pharmacological specificity of dopamine D2 and D3 receptors.
    Michino M; Donthamsetti P; Beuming T; Banala A; Duan L; Roux T; Han Y; Trinquet E; Newman AH; Javitch JA; Shi L
    Mol Pharmacol; 2013 Dec; 84(6):854-64. PubMed ID: 24061855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatic linker variations in novel dopamine D
    Di Biase C; Leitzbach L; Frank A; Zivkovic A; Stark H
    Arch Pharm (Weinheim); 2024 Aug; 357(8):e2400071. PubMed ID: 38736025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective D
    Manvich DF; Petko AK; Branco RC; Foster SL; Porter-Stransky KA; Stout KA; Newman AH; Miller GW; Paladini CA; Weinshenker D
    Neuropsychopharmacology; 2019 Jul; 44(8):1445-1455. PubMed ID: 30879021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition.
    Simpson EH; Winiger V; Biezonski DK; Haq I; Kandel ER; Kellendonk C
    Biol Psychiatry; 2014 Nov; 76(10):823-31. PubMed ID: 24387821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopamine D3/D2 Receptor Antagonist PF-4363467 Attenuates Opioid Drug-Seeking Behavior without Concomitant D2 Side Effects.
    Wager TT; Chappie T; Horton D; Chandrasekaran RY; Samas B; Dunn-Sims ER; Hsu C; Nawreen N; Vanase-Frawley MA; O'Connor RE; Schmidt CJ; Dlugolenski K; Stratman NC; Majchrzak MJ; Kormos BL; Nguyen DP; Sawant-Basak A; Mead AN
    ACS Chem Neurosci; 2017 Jan; 8(1):165-177. PubMed ID: 27715007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopamine D
    Gogarnoiu ES; Vogt CD; Sanchez J; Bonifazi A; Saab E; Shaik AB; Soler-Cedeño O; Bi GH; Klein B; Xi ZX; Lane JR; Newman AH
    J Med Chem; 2023 Feb; 66(3):1809-1834. PubMed ID: 36661568
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.